Skip to main content

Table 1 Mean or number (%). Range (Min-Max) and ANOVA of demographic and clinical baseline characteristics of groups

From: Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial

Characteristic

 

Groups

 

Total (n = 40)

Experimental (n = 20)

Control (n = 20)

F (p)

Age (yr). mean (Range)

66.30 (50–82)

67.80 (50–82)

64.80 (54–81)

0.95 (0.33)

Marital Status. number (%)

 Single

5 (12.5)

3 (15)

2 (10)

 

 Married

19 (47.5)

14 (70)

5 (25)

 

 Divorced/Separated

6 (15)

0 (0)

6 (30)

 

 Widow

10 (25)

3 (15)

7 (35)

 

Education level. Number (%)

 Any study

11 (27.5)

7 (35)

4 (20)

 

 Primary/ Secondary School

16 (40)

7 (35)

9 (45)

 

 Vocational training/ Qualifications

8 (20)

3 (15)

5 (25)

 

 University/ Superior education

5 (12.5)

3 (15)

2 (10)

 

Employed. number (%)

9 (22.5)

3 (15)

6 (30)

 

Weight (Kg). mean. (Range)*

72.98 (44–130)

72.71 (53.2–97)

73.25 (44–130)

0.01 (0.91)

Height (cm). mean. (Range)*

159.60 (147–171)

159.25 (148–170)

159.95 (147–171)

0.11 (0.74)

Body Mass Index (BMI). mean. (Range)

28.17 (16.17–47.79)

28.80 (20.70–39.91)

28.62 (16.17–47.79)

0.01 (0.92)

Overweight (BMI ≥ 25). number (%)

30 (75)

14 (70)

16 (80)

 

Waist perimeter (cm.). mean. (Range)

97.63 (68–147)

95.80 (75–120)

99.45 (68–147)

0.69 (0.41)

Hip perimeter (cm). mean. (Range)

110.19 (89–145)

111.85 (93–130)

108.53 (89–145)

0.72 (0.40)

Tumor grade. Number (%)

 Grade I

8 (20)

6 (30)

2 (10)

 

 Grade II

16 (40)

9 (45)

7 (35)

 

 Grade III

14 (35)

5 (25)

9 (45)

 

 Grade IV

2 (5)

0 (0)

2 (10)

 

Kind of treatments. Number (%)

 Surgery (S)

3 (7.5)

3 (15)

0 (0)

 

 S+ Chemotherapy (ChT)

3 (7.5)

0 (0)

3 (15)

 

 S+ Radiotherapy (RT)

15 (37.5)

10 (50)

5 (25)

 

 S+ ChT+ RT

19 (47.5)

7 (35)

12 (60)

 

Previous Tamoxifen (TMX). number (%)

9 (22.5)

3 (15)

6 (30)

 

TMX treatment duration (mo). mean. (Range)

4.46 (0–32)

4.30 (0–32)

4.64 (0–25)

0.01 (0.91)

Aromatase Inhibitors (AIs). number (%)

 Anastrozole (Arimidex®)

12 (30)

4 (20)

8 (40)

 

 Letrozole (Femara®)

23 (57.5)

14 (70)

9 (45)

 

 Exemestane (Aromasin®)

5 (12.5)

2 (10)

3 (15)

AIs treatment duration (mo). mean. (Range)

17.40 (2–52)

15.25 (2–52)

19.55 (2–44)

1.25 (0.27)

Comorbidities. number (%)

 Cervical pain

33 (82.5)

19 (95)

14 (70)

 

 Shoulder pain

34 (85)

18 (90)

16 (80)

 

 Lumbar pain

30 (75)

17 (85)

13 (65)

 

 Hands/ Wrist pain

25 (62.5)

12 (60)

13 (65)

 

 Hypertension

24 (60)

14 (70)

10 (50)

 

 Heart disease

8 (20)

3 (15)

5 (25)

 

 Circulation problems

23 (57.5)

12 (60)

11 (55)

 

 Thyroid problems

6 (15)

4 (20)

2 (10)

 

 Stroke

0 (0)

0 (0)

0 (0)

 

 Diabetes

5 (12.5)

2 (10)

3 (15)

 

 Gastric/ duodenal ulcer

1 (2.5)

0 (0)

1 (5)

 

 Breathing problems

6 (15)

2 (10)

4 (20)

 

 Parkinson

0 (0)

0 (0)

0 (0)

 

 Cognitive impairment

0 (0)

0 (0)

0 (0)

 

 Migraine/chronic headache

7 (17.5)

4 (20)

3 (15)

 

 Vision problems

13 (32.5)

7 (35)

6 (30)

 

 Hearing problems

10 (25)

6 (30)

4 (20)

 

Lymphedema

4 (10)

2 (10)

2 (10)

 
  1. *Self-reported weight and height